Immunomedics Financial Statements (IMMU)
|
|
|
|
Report date
|
|
|
19.08.2015 |
18.08.2016 |
16.08.2017 |
23.08.2018 |
27.02.2020 |
|
05.08.2020 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
5.65 |
3.23 |
3.09 |
2.16 |
0.295 |
|
40.1 |
|
Operating Income, bln rub |
|
|
-46.2 |
-59.0 |
-79.1 |
-141.0 |
-324.8 |
|
-270.0 |
|
EBITDA, bln rub |
? |
|
-45.3 |
-57.9 |
-146.8 |
-249.1 |
-321.0 |
|
-259.6 |
|
Net profit, bln rub |
? |
|
-48.0 |
-59.0 |
-153.2 |
-273.8 |
-357.2 |
|
-319.0 |
|
|
OCF, bln rub |
? |
|
-39.0 |
-48.5 |
-62.3 |
-134.0 |
-222.4 |
|
-205.4 |
|
CAPEX, bln rub |
? |
|
0.924 |
2.23 |
1.84 |
9.97 |
6.85 |
|
2.65 |
|
FCF, bln rub |
? |
|
-39.9 |
-50.7 |
-64.1 |
-143.9 |
-229.3 |
|
-208.0 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
9.87 |
7.59 |
30.0 |
43.3 |
70.3 |
|
306.8 |
|
Cost of production, bln rub |
|
|
42.0 |
54.7 |
52.3 |
99.9 |
254.9 |
|
3.34 |
|
R&D, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
210.0 |
|
Interest expenses, bln rub |
|
|
2.09 |
5.48 |
5.48 |
23.3 |
40.3 |
|
55.5 |
|
|
Assets, bln rub |
|
|
105.8 |
57.0 |
162.6 |
664.2 |
671.7 |
|
1 077 |
|
Net Assets, bln rub |
? |
|
-3.91 |
-56.8 |
-58.7 |
400.5 |
268.3 |
|
593.3 |
|
Debt, bln rub |
|
|
182.8 |
134.8 |
209.6 |
245.5 |
262.3 |
|
272.0 |
|
Cash, bln rub |
|
|
99.6 |
50.6 |
154.9 |
638.8 |
613.2 |
|
975.5 |
|
Net debt, bln rub |
|
|
83.2 |
84.2 |
54.7 |
-393.3 |
-350.9 |
|
-703.5 |
|
|
Ordinary share price, rub |
|
|
4.06 |
2.32 |
8.83 |
23.7 |
21.2 |
|
87.9 |
|
Number of ordinary shares, mln |
|
|
93.3 |
94.8 |
104.5 |
153.5 |
193.6 |
|
225.3 |
|
|
Market cap, bln rub |
|
|
379 |
220 |
923 |
3 633 |
4 097 |
|
19 797 |
|
EV, bln rub |
? |
|
462 |
304 |
978 |
3 239 |
3 746 |
|
19 093 |
|
Book value, bln rub |
|
|
-4 |
-57 |
-59 |
401 |
268 |
|
593 |
|
|
EPS, rub |
? |
|
-0.51 |
-0.62 |
-1.47 |
-1.78 |
-1.84 |
|
-1.42 |
|
FCF/share, rub |
|
|
-0.43 |
-0.53 |
-0.61 |
-0.94 |
-1.18 |
|
-0.92 |
|
BV/share, rub |
|
|
-0.04 |
-0.60 |
-0.56 |
2.61 |
1.39 |
|
2.63 |
|
|
EBITDA margin, % |
? |
|
-800.9% |
-1 790% |
-4 748% |
-11 555% |
-108 819% |
|
-646.6% |
|
Net margin, % |
? |
|
-849.1% |
-1 826% |
-4 956% |
-12 701% |
-121 081% |
|
-794.6% |
|
FCF yield, % |
? |
|
-10.5% |
-23.1% |
-6.94% |
-3.96% |
-5.60% |
|
-1.05% |
|
ROE, % |
? |
|
1 227% |
103.9% |
261.0% |
-68.4% |
-133.2% |
|
-53.8% |
|
ROA, % |
? |
|
-45.4% |
-103.7% |
-94.2% |
-41.2% |
-53.2% |
|
-29.6% |
|
|
P/E |
? |
|
-7.89 |
-3.72 |
-6.02 |
-13.3 |
-11.5 |
|
-62.1 |
|
P/FCF |
|
|
-9.49 |
-4.34 |
-14.4 |
-25.2 |
-17.9 |
|
-95.2 |
|
P/S |
? |
|
67.0 |
68.0 |
298.6 |
1 685 |
13 888 |
|
493.1 |
|
P/BV |
? |
|
-96.8 |
-3.87 |
-15.7 |
9.07 |
15.3 |
|
33.4 |
|
EV/EBITDA |
? |
|
-10.2 |
-5.25 |
-6.66 |
-13.0 |
-11.7 |
|
-73.5 |
|
Debt/EBITDA |
|
|
-1.84 |
-1.45 |
-0.37 |
1.58 |
1.09 |
|
2.71 |
|
|
R&D/CAPEX, % |
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
7 930% |
|
|
CAPEX/Revenue, % |
|
|
16.4% |
68.9% |
59.4% |
462.6% |
2 322% |
|
6.60% |
|
| Immunomedics shareholders |
